LifeCycle Pharma eyes several acquisition candidates  

2008.04.03
LifeCycle Pharma aims to take a significant slice of the market for transplantation drugs and is looking at potential acquisitions
Danish speciality pharmaceutical company LifeCycle Pharma is looking at acquisitions that can help the company to gain a significant slice of the market for transplantation drugs, writes financial daily newspaper Børsen. Managing director of LifeCycle Pharma Flemming Ørnskov says he has several potential candidates in mind:
 
"In times of crisis, it is a good idea to go on the offensive and look at acquisition opportunities. I think we will land a product this year or next year, and we have a major focus on this."
 
LifeCycle Pharma recently achieved promising test results with a drug candidate that prevents rejection of organs in kidney and liver transplant recipients. Ørnskov anticipates that the drug could be launched on the market in 2010 and could generate sales of up to USD 800m.

"In addition to this product, I would like our sales staff to have another product so that we can gain a larger slice of the transplantation market," says Ørnskov.
 
The global transplantation market is estimated to be worth USD 5-10bn, a figure which is growing due to better drugs and better technology making it possible to transplant organs at an earlier stage and in older patients.
 
LifeCycle Pharma is headquartered in Hørsholm north of Copenhagen and has a fully owned subsidiary in New York, USA. The company was founded in 2002 as a spin-off from Danish pharmaceutical company Lundbeck, and is listed on the OMX Nordic Exchange. LifeCycle Pharma utilizes its proprietary Meltdose technology to improve the bioavailability of known and established compounds so that patients can absorb them more effectively.
 
Link > LifeCycle Pharma   

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×